Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, CHINA, April 14, 2023 – Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced the company will present one poster concerning Phase 1 clinicalresults for BAT1006 at the 2023 American Association for Cancer Research("AACR") Annual Meeting taking ...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evaluating BAT8007,an antibody-drug conjugate (ADC) that targets Nectin-4. The multicenter,open-label Phase 1 clinica...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evaluating BAT8008,an antibody-drug conjugate (ADC) that targets Trop2. The multicenter,open-label Phase 1 clinical s...
